Correlation of Histopathological and Radiological Response Patterns and Their Prognostic Implications in Breast Cancer After Neoadjuvant Chemotherapy

被引:1
作者
Bozer, Ahmet [1 ,2 ]
Yilmaz, Cengiz [3 ]
Tuncez, Hulya cetin [1 ,2 ]
Cavdar, Demet Kocatepe [4 ]
Adibelli, Zehra Hilal [1 ,2 ,5 ]
机构
[1] Izmir City Hosp, Dept Radiol, Izmir, Turkiye
[2] Izmir Bozyaka Educ & Res Hosp, Dept Radiol, Izmir, Turkiye
[3] Izmir City Hosp, Dept Med Oncol, Izmir, Turkiye
[4] Izmir City Hosp, Dept Pathol, Izmir, Turkiye
[5] Univ Hlth Sci, Izmir Fac Med, Dept Radiol, Izmir, Turkiye
关键词
breast cancer; neoadjuvant chemotherapy; tumor shrinkage patterns; survival outcomes; radiologic response; GRADING SYSTEM; THERAPY; SHRINKAGE; SURVIVAL; SIZE;
D O I
10.2147/BCTT.S495553
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: In breast cancer (BC), neoadjuvant chemotherapy (NAC) responses can be categorized as concentric shrinkage (CS), non- concentric shrinkage (non-CS), and complete response, influencing surgical planning and survival. This study evaluates the correlation between histopathological and radiological response patterns in BC patients after NAC and their impact on overall survival (OS) and disease-free survival (DFS). Patients and Methods: This retrospective study analyzed 168 BC patients who received NAC between 2018 and 2022. Tumor response was evaluated radiologically using MRI and histopathologically after surgery. Radiological response patterns were categorized into CS, non-CS, and radiological complete response (rCR). Histopathologically, patients were classified into CS, non-CS, and pathological complete response (pCR). Concordance between radiological and histopathological classifications was assessed using the kappa statistic. Survival outcomes, including OS and DFS, were analyzed using Kaplan-Meier methods. Results: Histopathological response patterns were distributed as CS (31.5%), non-CS (34.5%), and pCR (34%). Moderate agreement was observed between radiological and histopathological assessments (kappa: 0.439, p < 0.001). Radiological evaluation identified 64% of CS, 50% of non-CS, and 74% of pCR cases accurately. Tumor molecular subtypes significantly correlated with both radiologic and histopathologic response patterns (p < 0.001). Subtype analysis revealed higher pCR rates in TN, HER2-enriched, and Luminal B-HER2(+) tumors, while non-CS was predominant in Luminal A tumors. No significant correlation was observed between histopathological or radiological patterns and OS (p: 0.291, p: 0.515) or DFS (p: 0.599, p: 0.899). However, patients achieving pCR tended to have better survival outcomes. Conclusion: We observed moderate concordance between histopathological and radiological response patterns in BC patients after NAC, but discrepancies highlight the limitations of radiological evaluation alone. These patterns did not significantly correlate with prognosis. Higher pCR rates were associated with better outcomes, but response patterns alone may not predict survival, warranting further research in larger cohorts.
引用
收藏
页码:1005 / 1017
页数:13
相关论文
共 27 条
[1]   Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution [J].
Antolin, Silvia ;
Acea, Benigno ;
Albaina, Luis ;
Concha, Angel ;
Santiago, Paz ;
Garcia-Caballero, Tomas ;
Mosquera, Joaquin J. ;
Ramon Varela, Jose ;
Soler, Rafaela ;
Calvo, Lourdes .
BREAST CANCER-TARGETS AND THERAPY, 2019, 11 :29-42
[2]   Pretreatment MR Imaging Features of Triple-Negative Breast Cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival [J].
Bae, Min Sun ;
Shin, Sung Ui ;
Ryu, Han Suk ;
Han, Wonshik ;
Im, Seock-Ah ;
Park, In-Ae ;
Noh, Dong-Young ;
Moon, Woo Kyung .
RADIOLOGY, 2016, 281 (02) :392-400
[3]   Magnetic resonance imaging tumor regression shrinkage patterns after neoadjuvant chemotherapy in patients with locally advanced breast cancer: Correlation with tumor biological subtypes and pathological response after therapy [J].
Ballesio, Laura ;
Gigli, Silvia ;
Di Pastena, Francesca ;
Giraldi, Guglielmo ;
Manganaro, Lucia ;
Anastasi, Emanuela ;
Catalano, Carlo .
TUMOR BIOLOGY, 2017, 39 (03)
[4]   Impact of Factors Affecting the Residual Tumor Size Diagnosed by MRI Following Neoadjuvant Chemotherapy in Comparison to Pathology [J].
Chen, Jeon-Hor ;
Bahri, Shadfar ;
Mehta, Rita S. ;
Carpenter, Philip M. ;
Mclaren, Christine E. ;
Chen, Wen-Pin ;
Fwu, Peter T. ;
Hsiang, David J. B. ;
Lane, Karen T. ;
Butler, John A. ;
Su, Min-Ying .
JOURNAL OF SURGICAL ONCOLOGY, 2014, 109 (02) :158-167
[5]   The Diagnostic Performance of DCE-MRI in Evaluating the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis [J].
Cheng, Qingqing ;
Huang, Jiaxi ;
Liang, Jianye ;
Ma, Mengjie ;
Ye, Kunlin ;
Shi, Changzheng ;
Luo, Liangping .
FRONTIERS IN ONCOLOGY, 2020, 10
[6]   Evaluation of the Tumor Response After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation Between Dynamic Contrast-enhanced Magnetic Resonance Imaging and Pathologic Tumor Cellularity [J].
Choi, Woo Jung ;
Kim, Won Kyung ;
Shin, Hee Jung ;
Cha, Joo Hee ;
Chae, Eun Young ;
Kim, Hak Hee .
CLINICAL BREAST CANCER, 2018, 18 (01) :E115-E121
[7]   De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 [J].
Curigliano, G. ;
Burstein, H. J. ;
Winer, E. P. ;
Gnant, M. ;
Dubsky, P. ;
Loibl, S. ;
Colleoni, M. ;
Regan, M. M. ;
Piccart-Gebhart, M. ;
Senn, H. -J. ;
Thurlimann, B. ;
Andre, F. ;
Baselga, J. ;
Bergh, J. ;
Bonnefoi, H. ;
Brucker, S. Y. ;
Cardoso, F. ;
Carey, L. ;
Ciruelos, E. ;
Cuzick, J. ;
Denkert, C. ;
Di Leo, A. ;
Ejlertsen, B. ;
Francis, P. ;
Galimberti, V. ;
Garber, J. ;
Gulluoglu, B. ;
Goodwin, P. ;
Harbeck, N. ;
Hayes, D. F. ;
Huang, C. -S. ;
Huober, J. ;
Khaled, H. ;
Jassem, J. ;
Jiang, Z. ;
Karlsson, P. ;
Morrow, M. ;
Orecchia, R. ;
Osborne, K. C. ;
Pagani, O. ;
Partridge, A. H. ;
Pritchard, K. ;
Ro, J. ;
Rutgers, E. J. T. ;
Sedlmayer, F. ;
Semiglazov, V. ;
Shao, Z. ;
Smith, I. ;
Toi, M. ;
Tutt, A. .
ANNALS OF ONCOLOGY, 2017, 28 (08) :1700-1712
[8]   Translating neoadjuvant therapy into survival benefits: one size does not fit all [J].
De Mattos-Arruda, Leticia ;
Shen, Ronglai ;
Reis-Filho, Jorge S. ;
Cortes, Javier .
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (09) :566-579
[9]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[10]   Pattern of Tumor Shrinkage during Neoadjuvant Chemotherapy Is Associated with Prognosis in Low-Grade Luminal Early Breast Cancer [J].
Fukada, Ippei ;
Araki, Kazuhiro ;
Kobayashi, Kokoro ;
Shibayama, Tomoko ;
Takahashi, Shunji ;
Gomi, Naoya ;
Kokubu, Yumi ;
Oikado, Katsunori ;
Horii, Rie ;
Akiyama, Futoshi ;
Iwase, Takuji ;
Ohno, Shinji ;
Hatake, Kiyohiko ;
Sata, Naohiro ;
Ito, Yoshinori .
RADIOLOGY, 2018, 286 (01) :49-57